04593nam 22008775 450 991088638390332120240318103733.00-7748-3386-610.59962/9780774833868(CKB)3710000001400363(MiAaPQ)EBC4873385(DE-B1597)661449(DE-B1597)9780774833868(EXLCZ)99371000000140036320230808h20172017 uy nengur||#||||||||txtrdacontentcrdamediacrrdacarrierHealth Advocacy, Inc. How Pharmaceutical Funding Changed the Breast Cancer Movement /Sharon BattVancouver, BC :University of British Columbia Press,[2017]©20171 online resource (396 p.)0-7748-3384-X Front Matter --Contents --Acknowledgments --Preface --Introduction --Canada’s Health Care System Transformed --Canada’s Health Policy Landscape --Health Advocacy Organizations in Canada --From Grassroots to Contestation to Partnership --Beginnings of the Breast Cancer Movement --Advocacy Redefined --The Movement Fractures over Pharma Funding --Pharma Funding as the New Norm --Advocacy Groups and the Continuing Struggle over the Pharma-Funding Question --Conclusion --Appendix --Notes --IndexOver the past several decades, a gradual reduction in state funding has pressured patient groups into forming private-sector partnerships, raising an important ethical question: do these alliances ultimately lead to policies that are counter to the public interest? Health activist, scholar, and cancer survivor Sharon Batt examines the issue by investigating Canada’s breast cancer movement from 1990 to 2010. Health Advocacy, Inc. dissects the relationship between the companies that sell pharmaceuticals and the individuals who use them, drawing links between neoliberalism and corporate financing and the ensuing threat to the public health care system. Combining archival analysis, interviews with advocacy and industry representatives, and personal observation, Batt argues that the resulting power imbalance continues to challenge the groups’ ability to put patients’ interests ahead of those of the funders. A movement that once encouraged democratic participation in the development of health policy now eerily echoes the demands of the pharmaceutical industry. Batt’s thorough account of this shift defines the stakes of activism in public health today.Patient advocacyCanadaBreastCancerResearchCanadaFinancePharmaceutical industryCanadaMedical policyCanadaPatient AdvocacyhistoryBreast NeoplasmsDrug IndustryhistoryDrug IndustryeconomicsPharmaceutical ResearcheconomicsHealth PolicyPatientsDroitsCanadaPatientsDroitsCanadaFinancesSeinCancerPatientsCanadaIndustrie pharmaceutiqueCanadaPolitique sanitaireCanadaBreastCancerResearchFinancefast(OCoLC)fst00838308Medical policyfast(OCoLC)fst01014505Patient advocacyfast(OCoLC)fst01055001Pharmaceutical industryfast(OCoLC)fst01060129CanadaCanadafastPatient advocacyBreastCancerResearchFinance.Pharmaceutical industryMedical policyPatient Advocacyhistory.Breast Neoplasms.Drug Industryhistory.Drug Industryeconomics.Pharmaceutical Researcheconomics.Health Policy.PatientsDroitsPatientsDroitsFinances.SeinCancerPatientsIndustrie pharmaceutiquePolitique sanitaireBreastCancerResearchFinance.Medical policy.Patient advocacy.Pharmaceutical industry.362.10971coll13local/laccBatt Sharonauthttp://id.loc.gov/vocabulary/relators/aut1769931DE-B1597DE-B1597BOOK9910886383903321Health Advocacy, Inc4245129UNINA